ArticleDiscover oncology2026
Clinical presentation and treatment of plasmablastic myeloma-a multicenter retrospective analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo report the clinical manifestations, laboratory tests, pathological features, diagnosis and treatment process and outcome of six patients with plasmablastic myeloma (PBM), and the clinical features and diagnosis and treatment methods of PBM were discussed in combination with literature.
methodsThe present study is a multicenter case series involving a small sample of six patients (n = 6). Clinical data of patients, such as age of onset, sex, pathological type, cytogenetic characteristics, disease stage, extramedullary disease were analyzed, and the efficacy evaluation and outcome after treatment were observed.
resultsAmong the 6 patients with PBM, 2 male and 4 female. The median age of the 6 patients was 63 (range 46-68) years. Three cases were newly diagnosed, three cases were found at the time of recurrence. The Ki-67 proliferation index of 5 cases was above 65%. Six cases all developed extramedullary infiltrates. Five cases were positive for 1q21 amplification. Four cases were negative for CD56 and one case was partially positive. Five patients died after multiple cycles of chemotherapy, and one patient is under treatment.
conclusionPBM has a low incidence, rapid cell proliferation, high tumor burden, multiple high-risk genetic abnormalities, rapid progression and poor prognosis. PBM frequently affects extramedullary sites. There is currently no standard treatment for PBM. CAR-T therapy may be a new option. Allogeneic hematopoietic stem cell transplantation is also the direction of exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.